The IG20 gene is overexpressed in human tumors and cancer cell lines, and encodes at least four splice variants (SVs) namely, IG20pa, MADD, IG20-SV2 and DENN-SV. Earlier, gain-of-function studies showed that IG20-SVs can exhibit diverse functions and play a critical role in cell proliferation and apoptosis. Expression of exogenous IG20pa or DENN-SV rendered cells either susceptible or resistant to induced apoptosis, respectively, whereas MADD and IG20-SV2 had no apparent effect. In order to understand the contrasting effects of the IG20-SVs in a physiologically more relevant system, we expressed exonspecific small hairpin RNAs (shRNAs) to selectively knockdown specific IG20-SVs. Consistent with an earlier study, knockdown of all IG20-SVs resulted in spontaneous apoptosis of HeLa and PA-1 cells. In addition, we unambiguously demonstrated that knockdown of MADD can render cells susceptible to spontaneous apoptosis but had no discernible effect on cell proliferation, colony size or cell cycle progression. Moreover, expression of MADD alone, and not DENN-SV, in the absence of endogenous IG20-SVs was sufficient to prevent spontaneous apoptosis. Our results show the utility of shRNAs for selective knockdown of particular IG20-SVs and their potential therapeutic value in cancer. Further, they demonstrate that MADD alone is sufficient and necessary for cancer cell survival.
Introduction
In eukaryotes, many genes undergo alternative splicing and encode multiple isoforms leading to the expression of related proteins with distinct biochemical as well as biological features (Andreadis et al., 1987) . The IG20 (Insulinoma-Glucagonoma) is one such gene that can encode at least four different splice variants (SVs), namely IG20pa (i.e., IG20 proapoptotic), MADD/ DENN, IG20-SV2 and DENN-SV (Goto et al., 1992; Lee, 1996, 1998; Cunningham, 1996; Schievella et al., 1997; Al-Zoubi et al., 2001) . These four IG20-SVs are distinguished by differential splicing of exons 13L and 16. Relative to IG20pa, MADD, IG20-SV2 and DENN-SV lack the expression of exon 16 or 13L or both (Al-Zoubi et al., 2001) .
The IG20 gene plays an important role in cancer cell proliferation, apoptosis and survival Lee, 1996, 1998; Schievella et al., 1997; Brinkman et al., 1999; Murakami-Mori et al., 1999; Telliez et al., 2000; AlZoubi et al., 2001; Lim and Chow, 2002; Efimova et al., 2003 Efimova et al., , 2004 Lim et al., 2004; Ramaswamy et al., 2004) . Additionally, it plays an important role in neurotransmission (Zhang et al., 1998; Tanaka et al., 2001; Yamaguchi et al., 2002) , neurodegeneration (Del Villar and Miller, 2004) and guanine nucleotide exchange (Wada et al., 1997; Brown and Howe, 1998; Iwasaki and Toyonaga, 2000; Levivier et al., 2001) . These divergent functions are most likely mediated through alternative splicing (Chow et al., 1998; Al-Zoubi et al., 2001; Efimova et al., 2004) .
Levels of expression of IG20 gene are higher in cancer cells and tissues relative to their normal counterparts. Although MADD and DENN-SV are constitutively expressed (DENN-SV is overexpressed relative to other SVs in cancer), expression of IG20pa and IG20-SV2 is regulated in that they may or may not be expressed in certain cells. This indicated that IG20pa and IG20-SV2 are not required for cell survival .
Previously, we carried out gain-of-function studies through expression of individual IG20-SVs in HeLa cells, and showed that MADD and IG20-SV2 variants have little or no effect on cell proliferation and induced apoptosis. Whereas IG20pa increased susceptibility to both extrinsic and intrinsic apoptotic stimuli, and suppressed cell proliferation, DENN-SV conferred resistance to induced apoptosis and enhanced cell proliferation. Thus, IG20pa and DENN-SV acted like a 'tumor suppressor' and an 'oncogene', respectively .
Knockdown of all endogenous IG20-SVs, using antisense oligonucleotides, resulted in spontaneous apoptosis of cancer cells in vitro and in vivo (Lim and Chow, 2002; Lim et al., 2004) . Therefore, contrasting effects of IG20-SVs, noted earlier, can only be clarified by knocking down individual IG20-SVs and determining the consequent effects. This posed several challenges because IG20-SVs differ from each other only by the differential expression of exons 13L (130 bp) and 16 (60 bp) (Al-Zoubi et al., 2001) . However, using small hairpin RNAs (shRNAs) that specifically target exons 13L, 15 and 16, we were able to selectively knock down either all or different combinations of IG20-SVs in HeLa and PA-1 cancer cell lines, and determine their role in cell survival. Our results demonstrate that MADD alone is necessary and sufficient for survival of these cancer cells.
Results

Small inhibitory RNAs can selectively knock down expression of exogenous IG20-SVs
To determine IG20-SVs that contribute to apoptosis and cell proliferation, we used small inhibitory RNAs (siRNAs) to selectively knock down IG20-SVs (Table 1) (McManus and Sharp, 2002; Cullen, 2004; Hall, 2004) . The siRNAs were cloned into the pSUPER vector (Brummelkamp et al., 2002) to allow for expression of shRNAs. We transfected 293T cells with either YFPIG20pa, YFP-MADD or YFP-DENN-SV, along with different shRNA-expressing pSUPER vectors at ratios of 1:1, 1:3 and 1:7, respectively. Reduction in YFP expression indicated knockdown of the relevant protein expression. Several shRNAs were screened and results for the most effective ones are shown in Figure 1a . The 13L-shRNA targeted to exon 13L downmodulated IG20pa/MADD, leaving the expression of DENN-SV unaltered. In contrast, 16E-shRNA targeted to exon 16, downmodulated IG20pa, but not MADD/DENN-SV. The Mid-shRNA targeted at exon 15, downmodulated all tested IG20-SVs. Vector alone or a control shRNA had little or no effect on the expression of IG20-SVs.
To further confirm specificity of Mid-shRNA, we created silent mutations in cDNAs encoding IG20-SVs at sites corresponding to the 5th, 7th, 11th and 14th nucleotides of the Mid-shRNA. These mutations neither affected the amino-acid sequence nor protein expression. Mutant IG20-SV constructs were co-transfected with the pSUPER-shRNA and assessed for their expression. Mid-shRNA failed to downmodulate the mutant proteins (Figure 1b) , further indicating the high specificity of the shRNA.
Small hairpin RNAs effectively knock down endogenous IG20-SVs We cloned shRNAs into a self-inactivating lentivirus vector (pNL-SIN-GFP) and generated SUP (vector control), Mid, 13L, 16E and SCR (negative control shRNA) constructs. This enabled us to monitor expression of double copy cassettes likely resulting in enhanced silencing (Cullen, 2005) . The transduction efficiency was over 80% as determined by GFP expression. Relative to controls (SUP and SCR), HeLa cells expressing MidshRNA showed decrease in expression levels of all IG20-SVs (Figure 2a ). 13L-shRNA and 16E-shRNA caused Although downmodulation of IG20pa/IG20-SV2 had no effect, abrogation of MADD/IG20pa led to increased spontaneous apoptosis. To see whether the underlying cause of spontaneous apoptosis was similar to that noted during apoptosis induced by either the extrinsic (caspase-8) or the intrinsic pathway (caspase-9), we determined the percentage of cells expressing active caspases-8 and -9 using flow cytometry.
Abrogation of MADD and IG20pa leads to increased caspase activation A general increase in caspase activation concomitant with increased apoptosis was observed in cells with reduced MADD expression ( Figure 4a ). Increased levels of both active caspases-8 and -9 were detected in cells treated with either Mid-or 13L-shRNA as early as 60 h (Figure 4b and c), and peaked at 72 h (not shown), postshRNA transduction, indicating activation of both extrinsic and intrinsic apoptotic pathways in cells lacking MADD.
Downmodulation of IG20-SVs has no apparent effect on HeLa cell proliferation
In order to assess the effects on cell growth and proliferation, various shRNA-expressing viable cells were counted. Relative to controls, a significant decrease in the numbers of viable cells expressing Mid-and 13L-shRNA was observed ( Figure 5a ). Lack of difference in CFSE dilution (SNARF-1 carboxylic acid, acetate, succinimidyl ester) over time between the control, Mid-and 13L-shRNA-treated cells suggested that the differences in cell numbers were not due to decreased proliferation ( Figure 5b ). Further confirmation was obtained by plating equal numbers of HeLa cells expressing various shRNAs and determining the number and size of colonies after 12 days. Although significantly fewer colonies were formed by Mid-and 13L-shRNA-expressing cells (panels d, e), the size of the colonies however, was comparable to that of controls. Further, shRNA-treated cells failed to show significant differences in cell cycle progression (not shown). Together, these results indicated that MADD abrogation primarily results in spontaneous apoptosis.
MADD knockdown in PA-1 ovarian carcinoma cells results in spontaneous apoptosis
In HeLa cells, we could either downmodulate all four, or a combination of IG20pa/MADD or IG20pa/IG20-SV2. To further demonstrate that MADD is required for cell survival, we employed PA-1 ovarian carcinoma cells that essentially express only MADD and DENN-SV MADD, and not DENN-SV, can prevent spontaneous apoptosis Knockdown of MADD alone in PA-1 cells led to spontaneous apoptosis. To see whether expression of DENN-SV alone would spare cells from undergoing enhanced spontaneous apoptosis, we co-expressed 13L and 16E shRNAs in HeLa cells and found increased spontaneous apoptosis. This further substantiated the critical requirement of MADD, and not DENN-SV, for cell survival (Figure 8 ).
In order to unambiguously demonstrate the essential role of MADD in cell survival, we generated HeLa cells stably expressing MADD-YFP-Mut and DENN-SV-YFP-Mut ( Figure 1b) . As shown in Figure 9a , 72 h post-transduction, the Mid-shRNA was unable to downmodulate either MADD-YFP-Mut or DENN-SV-YFP-Mut; whereas 13L-shRNA could downmodulate both endogenous as well as MADD-YFP-Mut. Interestingly, expression of MADD-YFP-Mut, and not DENN-SV-YFP-Mut, was sufficient to prevent the onset of spontaneous apoptosis in Mid-shRNA-treated Hela cells (Figure 9b ). Similar results were obtained in PA-1 cells (not shown). These results clearly demonstrate that MADD alone can prevent cancer cells from undergoing spontaneous apoptosis.
Discussion
Previously, gain-of-function studies using exogenous IG20-SVs showed that MADD and IG20-SV2 have little or no effect on cell proliferation and susceptibility to induced apoptosis. However, IG20pa rendered cells highly susceptible to apoptosis induced by different death signals including TRAIL, and suppressed cell proliferation. In contrast, we had found that DENN-SV is overexpressed in tumor tissues and cancer cell lines, and expression of exogenous DENN-SV could confer resistance to apoptosis and enhance cell proliferation (Al-Zoubi et al., 2001; Efimova et al., 2003 Efimova et al., , 2004 Ramaswamy et al., 2004) . These observations indicated that IG20-SVs could differentially regulate cell proliferation and death. Recent studies (Lim and Chow, 2002; Lim et al., 2004) in which all four endogenous IG20-SVs were knocked down using oligodeoxynucleotides (ODNs) revealed increased susceptibility of cancer cells to apoptosis; an intriguing finding given our previous Selective knockdown of IG20-SVs in cancer cell survival N Mulherkar et al observations. Therefore, we set out to determine the specific IG20-SV responsible for cancer cell survival.
In this study, we downmodulated select combinations of IG20-SVs using siRNAs. Synthetic siRNA duplexes (Elbashir et al., 2001a, b) or expressed shRNAs (Brummelkamp et al., 2002) can bind to the target mRNA and lead to its degradation (Hutva´gner and Zamore, 2002) . Specific and the most effective shRNAs against IG20-SVs were identified by screening five different shRNAs targeting all isoforms, and two each targeting exons 13L and 16 (Figure 1a) , and cloned into a lentivirus vector. Use of lentivirus resulted in stable expression of shRNAs that could be detected through GFP expression (Lee et al., 2003; Cullen, 2005) . Expressed shRNAs downmodulated only the targeted IG20-SVs (Figure 2 ) as early as 24 h post-transduction and lasted at least for 15 days (data not shown).
Significant increase in spontaneous apoptosis of HeLa cells with knockdown of all IG20-SVs was noted when assayed for nuclear condensation and mitochondrial depolarization; hallmarks of apoptosis (Kerr et al., 1972) . This is consistent with an earlier finding which showed spontaneous apoptosis of cancer, and not, normal cells following downmodulation of IG20-SVs using antisense ODNs (Lim and Chow, 2002) .
Significant spontaneous apoptosis was observed at 72 h, although the relevant IG20-SV transcripts were downmodulated by 24 h. This is likely due to persistence of pre-formed proteins, although the possibility that this duration is required for either accumulation of proapoptotic or downmodulation of antiapoptotic molecules cannot be ruled out.
Cancer cells die as a consequence of apoptosis owing to prolonged arrest in either G1/S or G2/M phases of cell cycle or owing to their inability to replicate (Johnstone et al., 2002) . We found that diminished viability of cells upon Mid-and 13L-shRNA expression (Figure 5a , c-g) was not due to defective cell proliferation (Figure 5b ) or perturbed cell cycle progression (not shown), but was a direct consequence of spontaneous apoptosis. Microscopic examination revealed similar colony size suggesting no significant changes in cell growth owing to knockdown of various IG20-SVs.
Apoptosis was consistently higher in 13L-treated relative to Mid-treated cells (Figures 3 and 6 ). However, this difference was obscured when a larger amount of Mid-shRNA virus was used (not shown), suggesting that relative to the amount of 13L-shRNA required to target IG20pa/MADD a larger amount of Mid-shRNA is required to knock down all four IG20-SVs.
As DENN-SV can act like an 'oncogene', we hypothesized that it might be required for cancer cell survival. Interestingly, significant increase in spontaneous apoptosis was observed when IG20pa/MADD, but not when IG20pa/IG20-SV2, were downmodulated (Figure 3 ) without affecting the levels of DENN-SV expression. This suggested that abrogation of MADD expression alone may induce spontaneous apoptosis of HeLa cells.
As compared to HeLa cells that express all four IG20-SVs, the PA-1 (ovarian carcinoma) cell line expresses predominantly MADD and DENN-SV , and thus allowed us to selectively knock down MADD. The results (Figures 6 and 7) on cell proliferation and cell cycle progression with PA-1 cells were very similar to that obtained using HeLa cells. Although the mode of action of MADD is not known, it can bind to death receptors (DRs) (Al-Zoubi et al., 2001 ) and thus might prevent spontaneous oligomerization of DRs that could lead to apoptosis. However, overexpression of exogenous MADD had no discernible effect on induced apoptosis (Al-Zoubi et al., 2001) . If the endogenous MADD (a prosurvival molecule) was sufficient to prevent DR oligomerization, expression of exogenous MADD would have little or no effect. On the other hand, either downmodulation of MADD (as done here), or expression of exogenous IG20pa (as we had done before), which might act as a dominant negative, could render cells susceptible to apoptosis by facilitating DR oligomerization. It is interesting to note that while IG20pa-enhanced TRAIL-induced apoptosis was accompanied by increased recruitment of death-inducing signaling complex and caspase activation; DENN-SV-induced resistance was characterized by enhanced nuclear factor-kB activation Ramaswamy et al., 2004) . Further studies are required to fully understand the mechanism of action of MADD and other SVs.
In summary, our study shows the utility of shRNAs for selective knockdown of IG20-SVs. Moreover, it shows the critical requirement of MADD for cancer cell survival and the potential clinical implication of selective abrogation of MADD.
Materials and methods
Design of small inhibitory RNAs
The siRNAs used are shown in Table 1 . Several putative siRNA sequences to target IG20 transcripts were obtained Selective knockdown of IG20-SVs in cancer cell survival N Mulherkar et al from the Dharmacon website (http://www.dharmacon.com/ sidesign). The most suitable sequences were sorted out based on less than 50% GC content, high AU content towards the 3 0 end and no inverted repeats within the siRNA region (Reynolds et al., 2004) .
Plasmid construction
The siRNAs were cloned into the pSUPER vector using BglII and HindIII sites (Brummelkamp et al., 2002) to generate pSMid, pS-13L, pS-16E and pS-SCR plasmids. The shRNA cassettes (including the H1 RNA promoter and the shRNA) were excised using XbaI and ClaI sites and ligated into the pNL-SIN-CMV-GFP vector (Lee et al., 2003) to generate SUP (vector control), Mid, 13L, 16E and SCR (negative control) lentivirus constructs. The pcTat, pcRev and pHIT/G were gifts from Dr BR Cullen and Dr TJ Hope. The IG20pa-YFP plasmid (Ramaswamy et al., 2004) was used as a backbone to subclone MADD-YFP and DENN-SV-YFP plasmids from respective pBKRSV plasmids (Al-Zoubi et al., 2001) using MluI and EcoRV sites. The DENN-SV-YFP-mut, MADD-YFP-mut and IG20-YFP-mut constructs were generated using the Quickchange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. Briefly, the primers 5 0 -CGGAACCACAGTACAAGCTT TAGCCTCTCAAACCTCACACTGCC-3 0 (forward) and 5 0 -GGCAGTGTGAGGTTTGAGAGGCTAAAGCTTGTACT GTGGTTCCG-3 0 (reverse) were used to insert four silent mutations (bold lettering) in the cDNAs without affecting the amino-acid sequence. HindIII site in the mutants, generated due to base substitutions, was used to identify positive clones that were confirmed by sequencing.
Cell culture 293T cells, HeLa cells and PA-1 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin-G and 100 mg/ml streptomycin. All cell lines were maintained at 371C in a humidified chamber with 5.5% CO 2 .
Screening of small hairpin RNAs IG20-YFP constructs were co-transfected with different pSUPER-shRNA constructs in different ratios (1:1, 1:3 and 1:7) into 293T cells using calcium phosphate. Twenty-four Lentivirus production Subconfluent 293T cells grown in 100 mm plates were cotransfected with 10.8 mg of lentivirus vector, 0.6 mg pcRev, 0.6 mg of pcTat and 0.3 mg of pHIT/G using calcium phosphate. Culture medium was replaced after 16 h, and the supernatant was harvested at 40 h and filtered using a 0.45 mm filter. The optimal viral titer for each cell type was determined as the least amount of viral supernatant required to transduce 80% of target cells without apparent cytotoxicity.
Reverse transcription-polymerase chain reaction Total RNA was extracted from 1 Â 10 6 transduced cells using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA), and 1 mg of RNA was used for reverse transcriptionpolymerase chain reaction (RT-PCR) using the Super-Script One-Step RT-PCR system (Invitrogen Life Technologies, Carlsbad, CA, USA). Briefly, the cDNAs were synthesized at 501C for 30 min followed by incubation at 941C for 2 min. Subsequently, 35 cycles of PCR were carried out with denaturation at 951C for 30 s, annealing at 551C for 30 s and extension at 721C for 1 min; followed by a final incubation at 721C for 7 min. The sequences of F2-B2 and GAPDH primers were as published (Al-Zoubi et al., 2001) . 13L-forward (5 0 -CGCCGGCGAATCTATGACAAT-3 0 ) and B2-reverse primers were used to amplify only MADD and IG20pa. The PCR products were then separated on a 2% agarose gel.
Hoechst staining 5 Â 10 5 transduced cells were washed in cold PBS. 5 mg/ml Hoechst 33342 (5 mg/ml) and 1 mg/ml propidium iodide (Sigma, St Louis, MO, USA) were used to stain cells for 5 min. Cells with condensed chromatin were analysed using a BD-LSR (Becton Dickinson, NJ, USA). Highly PI-positive cells representing necrotic or late-apoptotic cells were excluded from the analysis. Only GFP-positive cells were included in the analysis. ) were plated into sixwell plates. Twenty-four hours later, cells were treated with different shRNA-expressing lentiviruses for 4 h, washed and replenished with fresh warm medium. Twelve days later, cells were fixed in ice-cold methanol and stained with crystal violet to assess viability and colony formation.
Generation of HeLa cells expressing mutant proteins
HeLa cells were transfected with either MADD-YFP-mut, DENN-SV-YFP-mut or control EYFPC1 vector using SuperFect reagent (Qiagen Inc., CA, USA). Permanently transfected cells were selected in 800 mg/ml G418, and subsequently grown in a medium containing 400 mg/ml G418. Selective knockdown of IG20-SVs in cancer cell survival N Mulherkar et al
